<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04070313</url>
  </required_header>
  <id_info>
    <org_study_id>TTYTG1709</org_study_id>
    <nct_id>NCT04070313</nct_id>
  </id_info>
  <brief_title>A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan</brief_title>
  <official_title>A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TTY Biopharm</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer.&#xD;
&#xD;
        -  Primary Endpoint: Relapse-free survival (RFS)&#xD;
&#xD;
        -  Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate,&#xD;
           safety profile&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The time from registration to the time of initial detection of relapse or death from any causewhichever came first, assessed up to 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>The number of patient who occur relapse or death from any cause, whichever comes first before end of 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year relapse-free survival (RFS) rate</measure>
    <time_frame>2 years</time_frame>
    <description>the percentage of people in a study who are alive 2 years after their diagnosis or the start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence and percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v5.0 grade</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Resected Pancreatic Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Adjuvant Chemotherapy</condition>
  <arm_group>
    <arm_group_label>S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.</description>
    <arm_group_label>S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with resected adenocarcinoma pancreatic cancer that was histologically&#xD;
             verified.&#xD;
&#xD;
          2. Patients with macroscopic total resection of the primary tumor, and confirmed local&#xD;
             residual tumor classified as R0/R1.&#xD;
&#xD;
          3. Absence of distant metastases and malignant ascites&#xD;
&#xD;
          4. Adequate oral intake&#xD;
&#xD;
          5. Age of 20 years or above&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or1&#xD;
&#xD;
          7. Adequate hematopoietic which is defined as below,&#xD;
&#xD;
               -  White blood cell count: 3,000/mm3, ≤ 12,000/mm3&#xD;
&#xD;
               -  Platelet count: 100,000/mm3&#xD;
&#xD;
               -  Hemoglobin: 8.0 g/dL&#xD;
&#xD;
               -  ANC: 1500/mm3&#xD;
&#xD;
          8. CA19-9 ≤ 100 U/mL&#xD;
&#xD;
          9. Absence used of chemotherapy or radiotherapy&#xD;
&#xD;
         10. Within 10 weeks following resection of pancreatic cancer&#xD;
&#xD;
         11. Written informed consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient previously received adjuvant therapy for pancreatic cancer&#xD;
&#xD;
          2. Patient previously received S-1 treatment and concurrent using other&#xD;
             fluoropyrimidine-group anti-cancer drugs, combination therapies with them (such as&#xD;
             folinate plus Tegafur-Uracil combination therapy)&#xD;
&#xD;
          3. Recurrence prior to registration&#xD;
&#xD;
          4. Moderate or more severe pleural effusion or ascites upon abdominal CT&#xD;
&#xD;
          5. Inadequate hepatic function which is defined as below:&#xD;
&#xD;
               -  Total bilirubin greater than 1.5 times the ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)greater than&#xD;
                  2.5 times the ULN&#xD;
&#xD;
          6. Inadequate renal function which is defined as below:&#xD;
&#xD;
             Creatinine clearance rate (CCr) &lt; 60 mL/min&#xD;
&#xD;
          7. Heart failure of Class III (Marked limitation of physical activity. Comfortable at&#xD;
             rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.) or&#xD;
             Class IV (Unable to carry on any physical activity without discomfort. Symptoms of&#xD;
             heart failure at rest. If any physical activity is undertaken, discomfort increases.)&#xD;
             according to the New York Heart Association functional classification&#xD;
&#xD;
          8. Other serious complications such as active peptic ulcer, paresis of intestine or any&#xD;
             others&#xD;
&#xD;
          9. Pulmonary fibrosis or interstitial pneumonia clearly observed&#xD;
&#xD;
         10. Uncontrolled watery diarrhea Whether a patient has diarrhea 4 or more times a day&#xD;
             while receiving adequate supportive therapy will be used as the indicator to determine&#xD;
             whether watery diarrhea is inadequately controlled.&#xD;
&#xD;
         11. Blood transfusion within 2 weeks prior to registration&#xD;
&#xD;
         12. Myocardial infarction within 6 months following documentation of pancreatic cancer&#xD;
&#xD;
         13. An active infectious disease (pyrexia of 38°C or higher, etc.), including active&#xD;
             Hepatitis B or C.&#xD;
&#xD;
               -  Active HBV: HBeAg positive or HBeAg negative but HBV DNA &gt; 2000 IU/mL.&#xD;
&#xD;
               -  Active HCV: Anti-HCV Ab positive&#xD;
&#xD;
         14. Poorly controlled diabetes mellitus:&#xD;
&#xD;
             Fasting blood sugar ≥ 200 mg/dL or HbA1c ≥ 10.0 %&#xD;
&#xD;
         15. Participation in the study by the patient is judged difficult due to a complicating&#xD;
             psychiatric disorder or psychological symptoms&#xD;
&#xD;
         16. Patient is using drainage.&#xD;
&#xD;
         17. Serious drug allergy or hypersensitivity to the ingredients of S-1&#xD;
&#xD;
         18. Other malignancy with the exception of non-melanoma skin cancer or cervical carcinoma&#xD;
             in situ within 5 years prior to registration&#xD;
&#xD;
         19. Pregnant women or nursing mothers, or positive pregnancy test for women of&#xD;
             childbearing potential. Fertile women of childbearing potential unless using a&#xD;
             reliable and appropriate contraceptive method throughout the treatment period and for&#xD;
             three months following cessation of treatment.&#xD;
&#xD;
         20. Man who is willing to conceive a child during the treatment period.&#xD;
&#xD;
         21. On flucytosine, phenytoin or warfarin potassium treatment.&#xD;
&#xD;
         22. Participation in another clinical trial with any investigational drug within 30 days&#xD;
             prior to registration.&#xD;
&#xD;
         23. Patients who were judged to be ineligible as the subjects of this study by the&#xD;
             investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital_Linkou</name>
      <address>
        <city>Linkou</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>03-328-1200</phone>
      <email>lanhsiang416@nhri.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>06-7000123</phone>
      <email>Jeanyang@nhri.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02-23123456</phone>
      <email>lhy5471@nhri.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital, Taiwan</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02-2871-2121</phone>
      <email>jasminelin@nhri.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 25, 2019</last_update_submitted>
  <last_update_submitted_qc>August 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

